Market Signal Briefing

ENGLEWOOD, Colo., March 05, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”), a leader in renewable fuels and chemicals as well as carbon management, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided an update on operating performance, cash flow, and progress across its carbon management and synthetic aviation fuel (“SAF”) growth platform. A quarterly earnings presentation of the financial results will also be posted to the Company's website at https://investors.gevo.com/news-events/events-presentations.

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Apollo Global Management, Inc. (APO) Shareholders To Inquire About Securities Fraud Class Action.

Dr. Alan Baratz, CEO of D-Wave (QBTS), talks about what he calls a "great year" for the company in 2025, and the profitability path the latest earnings paves. He notes 2026 sales of D-Wave's quantum computing products already outpaced all of last year.

LIMASSOL, Cyprus, March 05, 2026 (GLOBE NEWSWIRE) -- GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its preliminary, unaudited financial and operational results for the fourth quarter and twelve months ended December 31, 2025.

Fourth quarter 2025 financial highlights:

Revenue of $90 million decreased by 8% year-over-year.Selling and marketing expenses of $35 million decreased by 25% year-over-year.Profit for the period, net of tax, of $14 million in Q4 2025 increased vs. $2 million in Q4 2024.Adjusted EBITDA1 of $15 million in Q4 2025 increased vs. $9 million in Q4 2024. Fourth quarter and twelve months 2025 financial performance in comparison

US$ millionQ4 2025Q4 2024Change (%)12M 202512M 2024Change (%)Revenue9098(8%)404421(4%)Platform commissions(18)(21)(13%)(85)(91)(7%)Game operation cost(15)(13)13%(57)(51)12%Selling and marketing expenses(35)(47)(25%)(159)(209)(24%)General and administrative expenses(9)(8)14%(35)(32)10%Profit/loss for the period, net of tax142N/M6926N/MAdjusted EBITDA215966%794287%Cash flows (used in)/generated from operating activities185N/M29293%
Fourth quarter 2025 financial performance

In the fourth quarter of 2025 our revenue decreased by $8 million (or 8%) year-over-year and amounted to $90 million, reflecting a decline in recognition of revenue from both current-period and prior-period bookings. This was mainly due to declining consumer spending levels in the current and preceding years, which reduced the amount of revenue recognized during the quarter. The decrease is consistent with our strategy to pursue more disciplined marketing spending and focus on attracting higher-quality, better-paying users rather than maximizing short-term volume.

Platform commissions decreased by $3 million (or 13%) in the fourth quarter of 2025 to reach $18 million, generally proportionate to the decrease in revenues.

Game operation cost increased by $2 million in the fourth quarter of 2025 and amounted to $15 million, mainly driven by an increase in investments in our IT infrastructure.

Selling and marketing expenses decreased by $12 million in the fourth quarter of 2025, amounting to $35 million. This decrease was driven by our continued focus on improving the efficiency of user acquisition activities. The decrease reflects a more selective approach to performance marketing, prioritizing channels that attract players with higher long-term value over broadscale campaigns aimed at short-term growth.

General and administrative expenses remained relatively stable at $9 million in the fourth quarter of 2025 vs. $8 million in the fourth quarter of 2024.

We recorded a profit for the period, net of tax, of $14 million in the fourth quarter of 2025 compared with $2 million in the same period of 2024, driven primarily by the factors above and i.) decrease of net financial expenses in Q4 2025 vs Q4 2024 in the amount of $3 million and ii.) decrease of share of loss of equity accounted associates by $6 million in Q4 2025 as compared with the same period of prior year. Adjusted EBITDA amounted to $15 million in the fourth quarter of 2025, an increase of $6 million compared with the same period in 2024 driven primarily by the same factors as those affecting the profit, except for the decrease of share of loss of equity accounted associates, which does not impact Adjusted EBITDA.

Cash flows generated from operating activities were positive $18 million in the fourth quarter of 2025 compared with positive $5 million in the same period in 2024.

Twelve months 2025 financial performance

In the year ended December 31, 2025, our revenue decreased by $17 million (or 4%) year-over-year and amounted to $404 million, reflecting a decline in recognition of revenue from both current-period and prior-period bookings. This was mainly due to declining consumer spending levels in the current and preceding years, which reduced the amount of revenue recognized during the year. The decrease is consistent with our strategy to pursue more disciplined marketing spending and focus on attracting higher-quality, better-paying users rather than maximizing short-term volume.

Platform commissions decreased by $7 million (or 7%) in the year ended December 31, 2025 to reach $85 million, generally proportionate to the decrease in revenues.

Game operation cost increased by $6 million in the year ended December 31, 2025 and amounted to $57 million, mainly driven by an increase in investments in our IT infrastructure.

Selling and marketing expenses decreased by $50 million in the year ended December 31, 2025, amounting to $159 million. This decrease was driven by our continued focus on improving the efficiency of user acquisition activities. The decrease reflects a more selective approach to performance marketing, prioritizing channels that attract players with higher long-term value over broadscale campaigns aimed at short-term growth.

General and administrative expenses increased by $3 million in the year ended December 31, 2025 and amounted to $35 million vs. $32 million in the year ended December 31, 2024. The increase was primarily driven by higher salary and related personnel expenses, reflecting the expansion of development activities and increased scale of operations across our game development studios.

We recorded a profit for the period, net of tax, of $69 million in the year ended December 31, 2025 compared with $26 million in the same period of 2024, driven primarily by the factors above and i.) decrease of net financial expenses in the year ended December 31 2025 vs the same period in 2024 in the amount of $7 million, ii.) increase in gain resulted from the change in fair value of share warrant obligation and other financial instruments by $3 million in the year ended December 31 2025 as compared with the same period of prior year and iii.) decrease of share of loss of equity accounted associates by $4 million in the year ended December 31, 2025 as compared with the same period of prior year. Adjusted EBITDA amounted to $79 million in the year ended December 31, 2025, an increase $37 million compared with the same period in 2024 driven primarily by the same factors as those affecting the profit, except for the increase in gain resulted from the change in fair value of share warrant obligation and other financial instruments and the decrease of share of loss of equity accounted associates, which do not impact Adjusted EBITDA.

Cash flows generated from operating activities remained the same, at $29 million, in the year ended December 31, 2025 vs. the same period of 2024. The divergence in earnings and cash flow dynamics reflects the significant impact of deferred revenue recognition on current-period income, which did not have a material effect on current-period cash flows.

Fourth quarter and twelve months 2025 operational performance comparison

 Q4 2025Q4 2024Change (%)12M 202512M 2024Change (%)Bookings ($ million)8894(7%)351404(13%)Bookings from in-app purchases8389(6%)331377(12%)Bookings from advertising45(18%)2027(25%)Share of advertising5.1%5.8%(0.7) p.p5.7%6.7%(1.0) p.p.MPU (thousand)262292(10%)281342(18%)ABPPU ($)1061024%98927%
Bookings declined in the fourth quarter and twelve months of 2025 to reach $88 million and $351 million, respectively, compared with $94 million and $404 million in the same period in 2024. The decline is primarily due to a decline in monthly paying users by 10% in the fourth quarter of 2025 vs. the same period in 2024 and by 18% in the year ended December 31, 2025 vs. the same period in 2024, which we attribute to the decrease of the user acquisition investments throughout 2024 and 2025, partially offset by an increase in ABPPU.

The share of advertisement sales as a percentage of total bookings decreased in the fourth quarter of 2025 to reach 5.1% compared to 5.8% in the same respective period in 2024 and decreased in the year ended December 31, 2025 to reach 5.7% compared to 6.7% in the same period in 2024. This decline was primarily driven by a global trend of declining CPM rates for advertising throughout 2024 and 2025.

Split of bookings by platformQ4 2025Q4 202412M 202512M 2024Mobile58%57%60%60%PC42%43%40%40%
In the fourth quarter of 2025 we recorded an increase in share of mobile to reach 58% vs. 57% in the same period in 2024 and decrease in share of PC to reach 42% vs. 43% in the same period in 2024. In the year ended December 31, 2025 the share in mobile and PC remained the same compared to same period in 2024.

Split of bookings by geographyQ4 2025Q4 202412M 202512M 2024US30%34%33%34%Asia18%21%19%22%Europe34%32%33%30%Other18%13%15%14%
Our split of bookings by geography in the fourth quarter and twelve months of 2025 vs. the same respective periods in 2024 saw a decrease in the share of bookings derived from the US and Asia and an increase in bookings derived from Europe and Other.

Note:

Due to rounding, the numbers presented throughout this release may not precisely add up to the totals. The period-over-period percentage changes are based on the actual numbers and may therefore differ from the percentage changes if those were to be calculated based on the rounded numbers.

The figures in this release are preliminary and unaudited. The Company’s 2025 Annual Report on Form 20-F, which will include the Company’s audited financial statements as of for the year ended December 31, 2025, is expected to be published within the prescribed filing period.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D and others have accumulated over 550 million installs and more than $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc.

Contacts:

Investor Relations
Roman Safiyulin | Chief Corporate Development Officer
[email protected]

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2024 Annual Report on Form 20-F, filed by the Company on March 31, 2025, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Presentation of Non-IFRS Financial Measures

In addition to the results provided in accordance with IFRS throughout this press release, the Company has provided the non-IFRS financial measure “Adjusted EBITDA” (the “Non-IFRS Financial Measure”). The Company defines Adjusted EBITDA as the profit/loss for the period, net of tax as presented in the Company's financial statements in accordance with IFRS, adjusted to exclude (i) goodwill and investments in equity-accounted associates' impairment, (ii) loss on disposal of subsidiaries, (iii) income tax expense, (iv) other financial income, finance income and expenses other than foreign exchange gains and losses and bank charges, (v) change in fair value of share warrant obligations and other financial instruments, (vi) share of loss of equity-accounted associates, (vii) depreciation and amortization, (viii) share-based payments expense and (ix) certain non-cash or other special items that we do not consider indicative of our ongoing operating performance. The Company uses this Non-IFRS Financial Measure for business planning purposes and in measuring its performance relative to that of its competitors. The Company believes that this Non-IFRS Financial Measure is a useful financial metric to assess its operating performance from period-to-period by excluding certain items that the Company believes are not representative of its core business. This Non-IFRS Financial Measure is not intended to replace, and should not be considered superior to, the presentation of the Company’s financial results in accordance with IFRS. The use of the Non-IFRS Financial Measure terms may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures.

Reconciliation of the profit for the period, net of tax to the Adjusted EBITDA

US$ millionQ4 2025Q4 202412M 202512M 2024Profit for the period, net of tax1426926Adjust for:    Income tax expense0.9155Adjusted finance income/expenses3(0.2)0.7(3)(2)Share of loss of equity-accounted associates2(1)548Change in fair value of share warrant obligations and other financial instruments(0.2)(0.6)(4)(0.9)Depreciation and amortization2276Share-based payments0.10.20.61Adjusted EBITDA1597942
______________________________
1 For more information, see section titled “Presentation of Non-IFRS Financial Measures” on the last two pages of this report, including the reconciliation of the profit for the period, net of tax to the Adjusted EBITDA.

2 The financial information presented for the comparative periods of 2024 may not reconcile exactly with the amounts previously published for those periods. This is due to the reclassification of the Impairment loss on loan receivables from Royal Ark to the Share of loss of equity-accounted associates line.

3 Adjusted finance income/expenses consist of finance income and expenses other than foreign exchange gains and losses and bank charges, net.

LEHI, Utah--(BUSINESS WIRE)--Pattern Group Inc. (NASDAQ: PTRN), a leader in accelerating brands on global ecommerce marketplaces leveraging proprietary technology and AI, today announced financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a defining year for Pattern. We delivered record results, exceeding our prior expectations and demonstrating our ability to scale with discipline,” said Dave Wright, Co-Founder and CEO of Pattern. “Our results were driven.

, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. 

Details of the company's participation are as follows:

Leerink Partners Global Healthcare Conference 2026
Details: Viking management will participate in a fireside chat and in 1-on-1 meetings
Conference Date: March 8-11, 2026
Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern on Tuesday, March 10, 2026
Location: Miami, FL 2026 Jefferies Biotech on the Beach Summit
Details: Viking management will participate in 1-on-1 meetings
Conference Dates: March 10-11, 2026
Location: Miami, FL A live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, a replay of the webcast will be available on the Viking website following the conference. 

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

SOURCE Viking Therapeutics, Inc.

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for Year
Achieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year
Delivers Positive Adjusted EBITDA for Full Year

SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025.

2025 Fourth Quarter and Full-Year Highlights
Highlights are for the fourth quarter and full year 2025, except where otherwise noted.

Total members

886,000 at year end, up 55% year over year
Revenue

$76 million in the fourth quarter, up 58% year over year$260 million for the full year, up 53% compared with 2024 GLP-1 Leadership

Omada has now supported more than 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024Published research demonstrating the effectiveness of Omada’s programs, including data showing members in our GLP-1 Care Track, compared with published real-world evidence, achieved greater average weight loss and largely maintained weight, on average, one year after discontinuing GLP-1 therapyAnnounced plans in November to launch a new prescribing offering that will combine Omada’s evidence-based behavior change program with medication management for anti-obesity medications, including GLP-1sToday, announced GLP-1 Flex Care, a new option that gives employers a structured way to connect eligible employees with clinical evaluation, prescribing, and ongoing medical oversight for GLP‑1s—alongside Omada’s lifestyle and behavioral support—without taking on employer financial coverage for GLP-1s, providing another flexible pathway to balance access, affordability, and durable outcomes across diverse GLP‑1 coverage strategies Program Innovation

During 2025, launched OmadaSpark and Meal Map, AI-powered tools that support members with wellness education alongside our human coachesIn February of 2026, announced Omada for Cholesterol to address a highly prevalent, often under‑treated condition that frequently co‑exists with diabetes, hypertension, and obesity, further strengthening its multi‑condition platform capabilities and expanding the scope of Omada’s cardiometabolic care “Our 2025 performance reflects a pivotal year for Omada, marked by strong growth, important profitability milestones, and continued momentum across our business,” said Sean Duffy, co‑founder and CEO of Omada Health. “We demonstrated GLP‑1 companion support innovation, advanced our member‑facing AI capabilities, and introduced meaningful program expansions—all designed to support our members in achieving durable health improvements and serving as a foundation for progress toward our long‑term mission to bend the curve of chronic disease.”

Other Fourth Quarter and Full Year 2025 Financial Highlights

Gross margin of 71% in the fourth quarter, up from 67% in Q4 2024, and gross margin of 66% for the year compared with 61% in 2024Non-GAAP gross margin of 73% in the fourth quarter, up from 69% in Q4 2024, and non-GAAP gross margin of 68% for the year compared with 63% in 2024Net income of $5 million in the fourth quarter, compared with a net loss of $8 million in Q4 2024, and a net loss of $13 million for the year compared with a net loss of $47 million in 2024Adjusted EBITDA of $8 million in the fourth quarter, compared with an adjusted EBITDA loss of $4 million in Q4 2024, and adjusted EBITDA of $6 million for the year compared with an adjusted EBITDA loss of $29 million in 2024Cash and cash equivalents of $222 million Please see the Non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.

Financial Outlook
For the year ending December 31, 2026, Omada expects:

Revenue in the range of $312 million to $322 million, with the midpoint representing 22% growth compared with 2025Adjusted EBITDA in the range of $7 million to $15 million We have not provided an outlook for net loss (GAAP) or a reconciliation of expected adjusted EBITDA to net loss (GAAP) because net loss (GAAP) on a forward-looking basis is not available without unreasonable effort due to the potential variability and complexity of the items that are excluded from adjusted EBITDA, such as loss on debt extinguishment; provision for income taxes; depreciation and amortization; share-based compensation; change in fair value of warrant liabilities; amortization of intangible assets; and loss on disposal of property and equipment.

Conference Call

Omada Health will host a conference call at 1:30 p.m. PT/4:30 p.m. ET today, March 5, 2026, during which management will discuss fourth quarter and full-year 2025 results.

A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months.

Those participating via conference call can pre-register using the following link:
https://register-conf.media-server.com/register/BI58c6d7a71730445093f7ea7c02d33e97

About Omada Health

Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding our GLP-1 leadership, plans to launch a new prescribing offering and the benefits of the offering, program innovation and related capabilities, ability to deliver measurable results, business trends, growth prospects and future financial and operating results, and our financial outlook.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, which is being filed at or around the date hereof.

All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.

Investor Relations Contact:
Allan Kells
[email protected]

Media Contact:
Rose Ramseth
[email protected]

Omada Health, Inc.Consolidated Balance Sheets (in thousands, except share and per-share amounts)(unaudited)  As of December 31,  2025   2024 Assets   Current assets   Cash and cash equivalents$222,036  $76,392 Accounts receivable, net(1) 34,585   23,417 Inventory 4,486   3,296 Deferred commissions, current 3,539   3,017 Prepaid expenses and other current assets(2) 8,288   6,937 Total current assets 272,934   113,059 Property and equipment, net 7,942   5,625 Operating lease right-of-use asset -   447 Deferred commissions, non-current 8,711   9,214 Intangible assets, net 2,414   4,263 Goodwill 13,240   13,240 Other assets 165   5,044 Total assets$305,406  $150,892     Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)   Current liabilities   Accounts payable(3)$10,276  $4,168 Accrued expenses and other current liabilities(4) 40,392   29,840 Operating lease liability, current -   415 Deferred revenue(5) 25,058   19,530 Total current liabilities 75,726   53,953 Long term debt -   29,771 Warrant liabilities, non-current -   2,252 Other liabilities, non-current -   285 Total liabilities 75,726   86,261 Commitments and contingencies   Redeemable convertible preferred stock, $0.001 par value per share; no shares and 120,689 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares and 118,219 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $455,588 as of December 31, 2025 and December 31, 2024, net of issuance costs -   449,034 Stockholders’ equity (deficit)   Common stock, $0.001 par value per share; 750,000 and 181,500 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 58,429 and 8,157 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively 58   8 Additional paid-in capital 686,366   59,555 Accumulated deficit (456,744)  (443,966)Total stockholders’ equity (deficit) 229,680   (384,403)Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)$305,406  $150,892  (1) Includes amounts from a related party of $22.8 million and $13.2 million as of December 31, 2025 and December 31, 2024, respectively.
(2) Includes amounts from a related party of $0.3 million and $0.1 million as of December 31, 2025 and December 31, 2024, respectively.
(3) Includes amounts from a related party of $1.0 million and $0 as of December 31, 2025 and December 31, 2024, respectively.
(4) Includes amounts from a related party of $4.9 million and $2.2 million as of December 31, 2025 and December 31, 2024, respectively.
(5) Includes amounts from a related party of $18.8 million and $13.2 million as of December 31, 2025 and December 31, 2024, respectively.

Omada Health, Inc.Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per-share data)(unaudited)  Three Months Ended
December 31, Year Ended
December 31, 2025   2024   2025   2024 Revenue       Services(1)$71,651  $45,438  $241,043  $157,789 Hardware(2) 4,195   2,540   19,167   12,011 Total revenue 75,846   47,978   260,210   169,800 Cost of revenue       Services(3) 13,768   10,834   51,839   42,520 Hardware 8,416   5,011   37,432   24,403 Total cost of revenue 22,184   15,845   89,271   66,923 Gross profit 53,662   32,133   170,939   102,877 Operating expenses       Research and development(4) 11,552   9,190   40,683   35,923 Sales and marketing(5) 24,613   18,089   90,044   68,053 General and administrative(6) 14,216   11,954   52,184   42,555 Total operating expenses 50,381   39,233   182,911   146,531 Operating income (loss) 3,281   (7,100)  (11,972)  (43,654)Other income (expense), net       Interest expense (13)  (1,097)  (2,534)  (4,506)Interest income 1,891   174   5,305   805 Loss on debt extinguishment -   -   (2,109)  - Change in fair value of warrant liabilities -   (227)  (1,468)  218 Total other expense, net 1,878   (1,150)  (806)  (3,483)Income (loss) before provision for income taxes 5,159   (8,250)  (12,778)  (47,137)Provision for income taxes -   -   -   - Net income (loss) and comprehensive income (loss)$5,159  $(8,250) $(12,778) $(47,137)        Net income (loss) per share       Basic$0.09  $(1.04) $(0.35) $(6.11)Diluted$0.08  $(1.04) $(0.35) $(6.11)        Weighted-average shares outstanding       Basic 58,056   7,951   36,639   7,721 Diluted 63,930   7,951   36,639   7,721  (1) Includes amounts from a related party of $49.5 million and $25.9 million for the three months ended December 31, 2025 and 2024, respectively and $157.7 million and $88.0 million for the year ended December 31, 2025 and 2024, respectively.
(2) Includes amounts from a related party of $3.1 million and $1.8 million for the three months ended December 31, 2025 and 2024, respectively and $12.1 million and $6.5 million for the year ended December 31, 2025 and 2024, respectively.
(3) Includes amounts from a related party of $1.2 million and $0.9 million for the three months ended December 31, 2025 and 2024, respectively and $5.0 million and $3.4 million for the year ended December 31, 2025 and 2024, respectively.
(4) Includes amounts from a related party of $0.6 million and $0.4 million for the three months ended December 31, 2025 and 2024, respectively and $2.2 million and $1.7 million for the year ended December 31, 2025 and 2024, respectively.
(5) Includes amounts from a related party of $6.8 million and $4.2 million for the three months ended December 31, 2025 and 2024, respectively and $26.1 million and $15.2 million for the year ended December 31, 2025 and 2024, respectively.
(6) Includes amounts from a related party of $0.4 million and $0.3 million for the three months ended December 31, 2025 and 2024, respectively and $1.5 million and $1.1 million for the year ended December 31, 2025 and 2024, respectively.

Omada Health, Inc.Share-based Compensation Summary (in thousands)(unaudited)  Three Months Ended
December 31, Year Ended
December 31, 2025
 2024
 2025
 2024
Services cost of revenue$65 $57 $169 $219Research and development 594  458  2,228  1,713Sales and marketing 1,255  621  3,918  2,602General and administrative 1,831  1,176  6,640  4,886Total share-based compensation expense$3,745 $2,312 $12,955 $9,420 Omada Health, Inc.Consolidated Statements of Cash Flows (in thousands)(unaudited)  Three Months Ended
December 31, Year Ended
December 31,  2025   2024   2025   2024 Operating activities       Net income (loss)$5,159  $(8,250) $(12,778) $(47,137)Adjustments to reconcile net loss to net cash provided by (used in) operating activities       Depreciation and amortization 1,447   1,278   5,491   4,803 Share-based compensation 3,745   2,312   12,955   9,420 Loss on debt extinguishment -   -   2,109   - Loss on disposal of property and equipment 6   -   8   2 Amortization of debt issuance costs -   98   285   389 Non-cash operating lease expense -   187   447   728 Change in fair value of warrants -   227   1,468   (218)Provision for credit losses(1) (296)  1,009   1,189   1,760 Amortization of deferred commissions 872   742   3,339   2,643 Changes in operating assets and liabilities       Accounts receivable(2) 7,157   871   (12,357)  (8,805)Inventory (1,338)  (1,527)  (1,190)  318 Prepaid expenses and other current assets(3) 161   (1,197)  (1,409)  (1,853)Deferred commissions (1,191)  (1,550)  (3,510)  (6,422)Other non-current assets 70   78   251   409 Accounts payable(4) 4,916   (1,089)  6,289   399 Operating lease liabilities -   (202)  (415)  (783)Accrued expenses and other current liabilities(5) 2,770   3,661   10,552   5,343 Deferred revenue(6) (2,099)  (3,180)  5,528   4,645 Other non-current liabilities -   45   -   180 Net cash provided by (used in) operating activities 21,379   (6,487)  18,252   (34,179)        Investing activities       Purchases of property and equipment (199)  (184)  (1,322)  (596)Capitalized internal-use software costs (1,147)  (785)  (4,510)  (3,267)Net cash used in investing activities (1,346)  (969)  (5,832)  (3,863)        Financing activities       Proceeds from exercise of stock options 3,375   1,284   9,368   3,329 Payment of deferred offering costs 1   (1,171)  (4,283)  (4,538)Repayment of Midcap term facility principal -   -   (30,963)  - Payment of debt extinguishment costs -   -   (1,430)  - Proceeds from initial public offering, net of underwriting discounts and commissions -   -   160,532   - Net cash provided by (used in) financing activities 3,376   113   133,224   (1,209)        Net increase (decrease) in cash and cash equivalents 23,409   (7,343)  145,644   (39,251)Cash and cash equivalents at beginning of period 198,627   83,735   76,392   115,643 Cash and cash equivalents at end of period$222,036  $76,392  $222,036  $76,392  (1) Includes changes in related party balances of $0.5 million and $0.2 million for the three months and year ended December 31, 2025 and 2024, respectively.
(2) Includes changes in related party balances of $9.1 million and $5.3 million for the three months and year ended December 31, 2025 and 2024, respectively.
(3) Includes changes in related party balances of $0.2 million and $0.1 million for the three months and year ended December 31, 2025 and 2024, respectively.
(4) Includes changes in related party balances of $1.0 million and $0 million for the three months and year ended December 31, 2025 and 2024, respectively.
(5) Includes changes in related party balances of $2.7 million and $0.7 million for the three months and year ended December 31, 2025 and 2024, respectively.
(6) Includes changes in related party balances of $5.7 million and $3.9 million for the three months and year ended December 31, 2025 and 2024, respectively.

Non-GAAP Financial Measures

We use certain financial measures not calculated in accordance with accounting principles generally accepted in the United States (“GAAP”) to supplement the financial information in our consolidated financial statements, which are presented in accordance with GAAP. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP operating expenses, non-GAAP operating expenses (as a % of revenue), adjusted EBITDA, adjusted EBITDA margin, and free cash flow.

We define non-GAAP gross profit and non-GAAP gross margin as gross profit and gross margin, excluding share-based compensation expense, amortization of intangible assets, and depreciation and amortization.

We define non-GAAP general and administrative expenses as total general and administrative expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP research and development expenses as total research and development expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP sales and marketing expenses as total sales and marketing expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP operating expenses as total operating expenses reported on our consolidated statements of operations, excluding share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment. We define non-GAAP operating expenses margin as non-GAAP operating expenses divided by GAAP total revenue reported on our consolidated statements of operations.

We define adjusted EBITDA as net loss and comprehensive loss reported on our consolidated statements of operations, excluding the impact of interest expense, interest income, change in fair value of warrant liabilities, loss on debt extinguishment, provision for income taxes, share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment.

Free cash flow is net cash used in operating activities less purchases of property and equipment and capitalized internal-use software costs.

We believe these non-GAAP financial measures, when taken collectively with GAAP financial information, are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making. However, there are a number of limitations related to the use of non-GAAP financial measures. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Metric

Total Members: A member is a person who is enrolled in one of our virtual care programs and that generated a billing event in the preceding 12 months. We believe growth in the number of members is a key indicator of the performance of our business for both investors and management as we monitor the performance of our business, as members primarily drive services revenue. The number of members depends, in part, on our ability to successfully market our services to new customers and channel partners, our ability to sell additional programs to existing customers and channel partners, and our ability to promote awareness of our programs among covered individuals and to encourage their enrollment.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile to the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Omada Health, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures - Adjusted EBITDA (in thousands)(unaudited)  Three Months Ended
December 31, Year Ended
December 31,  2025   2024   2025   2024          (in thousands, except percentages)GAAP net income (loss) and comprehensive income (loss)$5,159  $(8,250) $(12,778) $(47,137)Add:       Interest expense 13   1,097   2,534   4,506 Interest income (1,891)  (174)  (5,305)  (805)Change in fair value of warrant liabilities —   227   1,468   (218)Loss on debt extinguishment —   —   2,109   — Provision for income taxes —   —   —   — Share-based compensation expense 3,745   2,312   12,955   9,420 Amortization of intangible assets 440   501   1,851   2,007 Depreciation and amortization(1) 1,007   777   3,640   2,796 Loss on disposal of property and equipment 5   —   8   2 Adjusted EBITDA$8,478  $(3,510) $6,482  $(29,429)GAAP net income (loss) and comprehensive income (loss) margin (as a percentage of revenue) 6.8% (17.2)% (4.9)% (27.8)%Adjusted EBITDA margin (as a percentage of revenue) 11.2% (7.3)%  2.5% (17.3)% (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

Omada Health, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures  (in thousands)(unaudited)  Three Months Ended
December 31, Year Ended
December 31,  2025   2024   2025   2024          (in thousands, except percentages)GAAP gross profit$53,662  $32,133  $170,939  $102,877 Add:       Share-based compensation expense 65   57   169   219 Amortization of intangible assets 440   438   1,755   1,755 Depreciation and amortization(1) 927   683   3,294   2,406 Non-GAAP gross profit 55,094   33,311   176,157   107,257 GAAP gross margin (as a percentage of revenue) 70.8%  67.0%  65.7%  60.6%Non-GAAP gross margin (as a percentage of revenue) 72.6%  69.4%  67.7%  63.2% (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

GAAP Research and development expense$11,552  $9,190  $40,683  $35,923 Less:       Share-based compensation expense 594   458   2,228   1,713 Depreciation and amortization(1) 27   19   88   83 Non-GAAP research and development expense$10,931  $8,713  $38,367  $34,127 Non-GAAP research and development expense (as a % of revenue) 14%  18%  15%  20%        GAAP Sales and marketing expense$24,613  $18,089  $90,044  $68,053 Less:       Share-based compensation expense 1,255   621   3,918   2,602 Amortization of intangible assets —   63   94   252 Depreciation and amortization(1) 34   28   121   118 Non-GAAP sales and marketing expense$23,324  $17,377  $85,911  $65,081 Non-GAAP sales and marketing expense (as a % of revenue) 31%  36%  33%  38%        GAAP General and administrative expense$14,216  $11,954  $52,184  $42,555 Less:       Share-based compensation expense 1,831   1,176   6,640   4,886 Depreciation and amortization(1) 19   47   138   189 Loss on disposal of property and equipment 5   —   8   2 Non-GAAP general and administrative expense$12,361  $10,731  $45,398  $37,478 Non-GAAP general and administrative expense (as a % of revenue) 16%  22%  17%  22%        GAAP operating expense$50,381  $39,233  $182,911  $146,531 Less:       Share-based compensation expense 3,680   2,255   12,786   9,201 Amortization of intangible assets —   63   94   252 Depreciation and amortization(1) 80   94   347   390 Loss on disposal of property and equipment 5   —   8   2 Non-GAAP operating expense$46,616  $36,821  $169,676  $136,686 GAAP operating expense (as a % of revenue) 66.4%  81.8%  70.3%  86.3%Non-GAAP operating expense (as a % of revenue) 61.5%  76.7%  65.2%  80.5% (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

Omada Health, Inc. Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow        (in thousands)       (unaudited)        Three Months Ended
December 31, Year Ended
December 31,  2025   2024   2025   2024 Net cash provided by (used in) operating activities$21,379  $(6,487) $18,252  $(34,179)Purchases of property and equipment (199)  (184)  (1,322)  (596)Capitalized internal-use software development costs (1,147)  (785)  (4,510)  (3,267)Free Cash Flow$20,033  $(7,456) $12,420  $(38,042)Other cash flow components:       Net cash used in investing activities$(1,346) $(969) $(5,832) $(3,863)Net cash provided by (used in) financing activities$3,376  $113  $133,224  $(1,209)

March 05, 2026 16:05 ET  | Source: CAMP4 Therapeutics

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026

Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties

Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028

CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the full year ended December 31, 2025, and provided recent corporate highlights.

"In 2025, we brought our SYNGAP1 program to the forefront of our pipeline and made significant progress against our goal of bringing a potential first-in-class treatment for SYNGAP1-related disorder into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “Our GLP toxicology studies for CMP-002 are ongoing, and we continue to expect to initiate a global first-in-human Phase 1/2 clinical trial as early as the second half of 2026. We also made progress in our mission of developing potentially disease modifying medicines for patients with disorders marked by suboptimal gene expression by exploring new candidates for both in-house development and potential partnerships and signed a collaboration agreement with GSK to identify and develop ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. Finally, we strengthened our balance sheet through a combination of equity financing and non-dilutive capital from collaboration partners to ensure that CAMP4 is well-capitalized to achieve its goals.”

Corporate Highlights:

Presented compelling preclinical data for SYNGAP1 program showing that haploinsufficient SYNGAP1 mice treated with CMP-002 demonstrated an increase in SYNGAP1 protein levels and that treatment rescued multiple SYNGAP1-dependent behavioral phenotypes. This data further demonstrated that CMP-002 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs).Initiated GLP toxicology studies for CMP-002 in support of future clinical trial applications, which could enable initiation of a global Phase 1/2 clinical trial in patients as early as H2 2026.Entered a strategic research, collaboration, and license agreement with GSK to identify and develop antisense nucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. CAMP4 received a $17.5 million cash upfront payment and has the potential to receive up to $440 million upon achievement of certain development and commercial milestones, in addition to tiered royalties on future product sales.Completed oversubscribed private placement for gross proceeds of up to $100 million, $50 million of which was received in the form of an upfront payment in September, as well as underwritten offering of common stock with gross proceeds of $30 million in December to fund further development of CMP-002.Conducted analysis from single ascending dose (SAD) and multiple ascending dose (MAD) portions of the CMP-001 Phase 1 clinical trial and made strategic decision to pause further investment in the development of CMP-001 and explore potential partnership opportunities.
Full Year 2025 Financial Results

Cash and cash equivalents as of December 31, 2025, were $109.5 million, compared to $64.0 million as of December 31, 2024. The Company believes that its current cash and cash equivalents will be sufficient to fund its planned activities into 2028.

R&D Expenses: Research and development (“R&D”) expenses for the year ended December 31, 2025, were $38.2 million, compared to $38.8 million for the year ended December 31, 2024. The decrease was primarily driven by a gain on lease modification and decreased clinical costs associated with CMP-001.

G&A Expenses: General and administrative (“G&A”) expenses were $17.4 million for the year ended December 31, 2025, compared to $14.9 million for the year ended December 31, 2024. The change was primarily driven by an increase in professional expenses.

Net Loss: Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024. The increase in net loss was primarily driven by a $29.8 million non-cash loss recognized due to a change in fair value of the derivative tranche liability related to our September private placement.

About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning the anticipated timing to advance the Company’s SYNGAP1 program into a clinical trial; the Company’s plan to pursue partnership opportunities to support the further development of CMP-001; the development of ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications; the potential of the Company’s platform technology; the Company’s receipt of future contingent milestones and/or royalties; the potential to receive up to $50 million in additional gross proceeds in connection with the Company’s September 2025 private placement; the Company’s strategy, goals, business plans and focus; the therapeutic potential of the Company’s product candidates; and the Company’s cash runway guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
[email protected]

Media:
Sofia Bermudez
LifeSci Communications
[email protected]

 CAMP4 Therapeutics Corporation
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except for share and per share data)
 ​Year ended December 31,​ 2025   2024 Revenue​ ​Research and collaboration revenue$3,498  $652 Operating expenses​ ​Research and development 38,202   38,817 General and administrative 17,357   14,923 Impairment of right-of-use asset 494   — Total operating expenses 56,053   53,740 Loss from operations (52,555)  (53,088)Other (expense) income, net:​ ​Interest income 2,174   1,330 Change in fair value of derivative tranche liability (29,830)  — Other expense (192)  (33)Total other (expense) income, net (27,848)  1,297 Net loss$(80,403) $(51,791)Net loss per share attributable to common stockholders, basic and diluted$(2.65) $(11.04)Weighted average shares of common stock outstanding, basic and diluted 30,380,567   4,690,094 ​
December 31,​Condensed Balance Sheet Data 2025   2024 (in thousands)​ ​Cash and cash equivalents$109,517  $64,039 Working capital(1)​98,581  56,785 Total assets 117,808   78,307 Total liabilities 70,104   15,163 Accumulated deficit (292,156)  (211,753)Total stockholders' equity 47,704   63,144  (1) Working capital is defined as total current assets less total current liabilities. See our consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, for further details regarding our current assets and current liabilities.

Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 and FY 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah's Q4 and FY 2025 Earnings Call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

ENGLISH_4Q&FY25 Earnings Call Announcement

Day One Biopharmaceuticals is maintained at a "Strong Buy" rating, driven by robust pipeline progress and multiple upcoming catalysts. The company's OJEMDA achieved FDA approval and delivered 172% year-over-year revenue growth in 2025, with label expansion efforts underway in pivotal phase 3 trial. Two novel ADC programs, Emi-Le and DAY-301, target high-value oncology indications, with key clinical data readouts expected in mid- and late 2026.

UniQure needs to run another study to prove that its gene therapy "actually helps people with Huntington's disease," a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn't ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

"So what is really going on? UniQure is the latest company to make a failed therapy for Huntington's patients," the official said. "They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA."

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC's Becky Quick last week seemingly criticized UniQure's gene therapy for Huntington's disease. Makary didn't name UniQure but described its treatment.

watch now

UniQure then accused the FDA of reversing its stance that the company's clinical trial data would be sufficient to seek approval. UniQure's study used an outside database to measure how patients with Huntington's disease might decline without treatment, known as an external control. UniQure has said it wouldn't be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn't be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency "never agreed to accept this distorted comparison" and the FDA "never makes such assurances." Instead, the "FDA will always say, 'Well, we have to see the data when we get it.'"

UniQure didn't immediately comment.

The company's stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.

HomeStock IdeasQuick Picks & Lists

SummaryPeriods of persistent inflation, higher interest rates, and geopolitical tension can create a challenging environment for investors.Companies that can provide a defensive and diversified mix in this macro backdrop, including hard assets, resilient consumer demand, income-generating real estate, and tech infrastructure.By combining reliable dividends backed by outstanding profitability, five companies illustrate how investors can build portfolios that can withstand volatility while maintaining exposure to potential upside in 2026.I am Steven Cress, Head of Quantitative Strategies at Seeking Alpha. I manage the quant ratings and factor grades on stocks and ETFs in Seeking Alpha Premium. I also lead Alpha Picks, which selects the two most attractive stocks to buy each month, and also determines when to sell them. Olivier Le Moal/iStock via Getty Images

Dividend Stocks That Can Thrive in a Challenging 2026 Macro Backdrop Investors entered 2026 expecting inflation to moderate, interest rates to gradually fall, and geopolitical tensions to remain modestly high but contained. However, reality has presented a more challenging set of circumstances. A resilient labor

87.38K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. Steven Cress is the Head of Quantitative Strategy at Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Permanent TSB Group Holdings plc (ILPMY) Q4 2025 Earnings Call Transcript

Varonis Systems, Inc. (VRNS) Morgan Stanley Technology, Media & Telecom Conference 2026 March 5, 2026 12:15 PM EST

Company Participants

Brian Vecci - Field C.T.O
Guy Melamed - CFO & COO

Conference Call Participants

Meta Marshall - Morgan Stanley, Research Division

Presentation

Meta Marshall
Morgan Stanley, Research Division

All right. Welcome, everybody. While we get situated, I'll read the disclosures real quick. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

I'm Meta Marshall. I cover cybersecurity here at Morgan Stanley. We're delighted to have Varonis, Guy Melamed, CFO; Brian Vecci, CTO.

Question-and-Answer Session

Meta Marshall
Morgan Stanley, Research Division

All right. Perfect. Maybe just to kind of start with in terms of -- just those who are kind of less familiar with Varonis or kind of data security in general, just kind of giving an overview of the company.

Brian Vecci
Field C.T.O

So where I'd start is almost all aspects of cybersecurity touches on data. Nobody breaks into a bank to steal the pens, they're after money. Nobody gets access to an account, an identity, an API these days, an agent, your infrastructure unless they're really after data. Companies face when it comes to data because they have so much not just in data centers these days, but in various cloud platforms, all of the hyperscalers, the applications, all of the AI workloads that they're building. They face a lot of regulatory risk. What do I have? Where is it? Are all the right controls in place, a lot of reputational risk. They don't want to be on the front page of the Wall Street Journal because they got breached.

And they need to do more with less. They need to

Q4: 2026-03-05 Earnings SummaryEPS of $1.27 beats by $0.09

 |

Revenue of

$1.74B

(28.39% Y/Y)

beats by $69.23M

Endeavour Mining plc (EDV:CA) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST

Company Participants

Jack Garman - Vice President of Investor Relations
Ian Cockerill - CEO & Executive Director
Guy Young - Executive VP & CFO
Djaria Traore - Executive Vice President of Operations & ESG

Conference Call Participants

Alain Gabriel - Morgan Stanley, Research Division
Ovais Habib - Scotiabank Global Banking and Markets, Research Division
Fahad Tariq - Jefferies LLC, Research Division
Marina Calero Ródenas - RBC Capital Markets, Research Division
Frederic Bolton - BMO Capital Markets Equity Research
Mohamed Sidibe - National Bank Financial, Inc., Research Division
Daniel Major - UBS Investment Bank, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to Endeavour Mining's Fourth Quarter and Full Year 2025 Results Webcast. [Operator Instructions] Today's conference call is being recorded, and a transcript of the call will be available on Endeavour's website tomorrow.

I would now like to hand the call over to Endeavour's Vice President of Investor Relations, Jack Garman. Please go ahead.

Jack Garman
Vice President of Investor Relations

Hello, everyone, and welcome to Endeavour's Q4 and Full Year 2025 Results Webcast.

Before we start, please note our usual disclaimer. On the call today, I'm delighted to be joined by Ian Cockerill, Chief Executive Officer; Guy Young, Chief Financial Officer; and Djaria Traore, Executive Vice President of Operations and ESG.

Today's call will follow our usual format. Ian will first go through the highlights of the quarter and the year, Guy will present the financials, and Djaria will walk through our operating results by mine before handing back to Ian for his closing remarks. We'll then open the line up for questions.

With that, I'll now hand over to Ian.

Ian Cockerill
CEO & Executive Director

Thank you, Jack, and hello to everyone who's joining us on the

Orlando, FL, March 05, 2026 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology (“DAVD”), will host a conference call on Tuesday, March 17, 2026 at 10:00 a.m. Eastern time to discuss its results for its Fiscal First Quarter 2026 ended January 31, 2026 (“FQ2026”). A press release detailing these results will be issued before the opening of trading on March 17, 2026.

The Company’s management will provide prepared remarks, followed by a question-and-answer period.

Date: Tuesday, March 17, 2026
Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)
U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879
International number: 1-201-389-0879
Conference ID: 13758973

The conference call will broadcast live and be available for replay here.

Persons interested in attending are required to call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please press *0.

A replay of the call will be available after approximately 2:00 p.m. Eastern time on the same day through Tuesday, March 31, 2026 at 11:59 p.m. ET.

Telephone replay numbers: 1-844-512-2921 or 1-412-317-6671
International replay number: 1-412-317-6671
Access ID: 13758973

About Coda Octopus Group, Inc.

The Company, founded in 1994, is an established supplier to the underwater/subsea market. It supplies a range of hardware and software solutions which includes key proprietary real time 4D/5D/6D imaging sonars, marketed under the name Echoscope®, Echoscope PIPE® and Echoscope PIPE NANO Gen Series® addressing the underwater imaging sensor market along with new generation diving technology, known as the Diver Augmented Vision Display (“DAVD”) system. The Company’s Echoscope PIPE® sonar generates real-time 3D/4D/5D images of moving objects underwater including in zero visibility water conditions. Echoscope technology is used globally for numerous applications in both the commercial offshore market and defense underwater markets. Applications for the Echoscope® technology include complex mapping underwater, subsea intervention, subsea asset placements, salvage and recovery, search and rescue, offshore renewables cable installations and surveys, marine construction, subsea infrastructure installation, mining applications, robotics (3D Perception and Depth), breakwater construction and monitoring, decommissioning, diving applications and port and harbor security.

The recently launched new generation of diving technology, DAVD, has the potential to change the way global diving operations are performed (both in the Defense and Commercial space) because it is a fully integrated singular system for topside control and fully connected diver HUD system, allowing both the topside and diver to share a range of critical information and visualize the same underwater scene. Furthermore, the DAVD integrates the Company’s sonar technology, which allows dive operations to be performed in zero visibility conditions, a common problem that besets these operations.

The Company also includes two discrete Defense Engineering Services businesses Coda Octopus Martech Ltd (UK based) and Coda Octopus Engineering, Inc. (US based) whose primary business model is to supply sub-assemblies into broader mission critical programs in the capacity of sub-contractors to the Prime Defense Contractors. Their scope of supply under these programs typically includes concept, design, prototype, manufacturing, and post-sale support. This gives them the opportunity to have repeat orders for these sub-assemblies through the life of these programs.

The Company recently acquired Precision Acoustics Limited, an acoustics sensor and materials business. PAL is a supplier of acoustic sensors and materials. PAL also performs calibration services for medical devices and is accredited to ISO/IEC 17025 standard. PAL is one of only two organizations in the United Kingdom with this certification, alongside the National Physical Laboratory (NPL). Globally, only a handful of facilities hold ISO/IEC 17025 accreditation for these measurements. Ultrasonic free-field sensitivity calibration is critical for markets that require precision ultrasonic measurement, strict safety compliance, and full metrological traceability. These include regulated and high-risk applications, such as diagnostic and therapeutic medical ultrasound and defense and underwater acoustics, where free-field calibration is essential to ensure accurate beam sensitivity and minimal interference. PAL’s operations are based in the United Kingdom.

For further information, please visit http://www.codaoctopusgroup.com or contact us at [email protected].

Forward Looking Statements

This press release contains forward-looking statements concerning Coda Octopus Group, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “assume” and similar expressions are intended to identify forward‐looking statements. Those forward-looking statements include, without limitation, statements regarding the Company's expectations for the growth of the Company's operations and revenue. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, fluctuations in foreign exchange rates, changes in global economic condition, tariff and trade policies, reduction in government spending in the Defense Sector, customer demand, geopolitical issues, the outcome of our ongoing research and development efforts relating to our products including our patented real time 3D solutions or DAVD; our ability to develop the sales force required to achieve our development and other examples of forward looking statement set forth in our Annual Report on Form 10-K for the year ended October 31, 2025, filed with the Securities and Exchange Commission on January 29, 2026 as amended on our Form 10-K/A, filed with the Securities and Exchange Commission on February 26, 2026. Coda Octopus Group, Inc., does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:
Mr. Dillon King
Coda Octopus IR Team at [email protected]
Coda Octopus Group, Inc.
1- 407-735-2406

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Farmer Brothers Co. (NASDAQ: FARM) related to its sale to Royal Cup, Inc. Under the terms of the proposed transaction, Farmer shareholders are expected to receive $1.29 per share in cash. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/farmer-brothers-co/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Apozeal Pharmaceutical Inc. (“Apozeal”), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines.

The proposed transaction represents a strategic step in advancing Tevogen Generics, established to support domestic pharmaceutical manufacturing and enhance affordability and national supply chain resilience.

If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including:

11 FDA-approved Abbreviated New Drug Application (ANDA) products for the U.S. marketMultiple ANDAs currently filed with the U.S. Food and Drug Administration awaiting approvalAdditional generic products in development Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “Tevogen Generics was launched with the objective of supporting pharmaceutical affordability and domestic manufacturing in the United States. The potential acquisition of Apozeal represents a meaningful step toward that strategy. With FDA-approved ANDA assets and a growing development pipeline, Apozeal could provide a foundation for building a revenue-generating generics business and could support Tevogen’s broader plan to expand U.S.-based pharmaceutical manufacturing.”

The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions.

Tevogen is also actively considering other transactions with a focus on life sciences-related businesses; however, there can be no assurance that any such transaction will be consummated.

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction with Apozeal and the potential benefits of the transaction; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction with Apozeal; the risk that the transaction with Apozeal may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction with Apozeal may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Distribution Solutions Group, Inc. (Nasdaq: DSGR) for potential securities law violations. Investors who have lost money in their Distribution Solutions Group investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/dsgr. 

What is this all about?

Shares of Distribution Solutions Group fell over 25% on March 5, 2026, after the company reported Q4 2025 results. On their Q4 earnings call, CEO Bryan King stated that the company had “navigated challenging headwinds in 2025…including those driven by fluid tariffs.” However, when asked whether the company felt like it had its “arms around” tariffs just months earlier at a November 18, 2025, conference, CFO Ron Knutson responded: “Yes, yes, yes, we can. We can plan around it,” and added that “we [the company] feel like we've been in a pretty good place around the tariff side.” Block & Leviton is investigating.

Who is eligible?

Anyone who purchased Distribution Solutions Group common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.

Whistleblower?

If you have non-public information about Distribution Solutions Group, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected] 

Impala Platinum Holdings Limited (IMPUY) Q2 2026 Earnings Call March 5, 2026 4:30 AM EST

Company Participants

Nicolaas Muller - CEO & Executive Director
Patrick Morutlwa - Group Chief Operating Officer
Meroonisha Kerber - CFO, Debt Officer & Executive Director
Johan Theron - Group Executive of Corporate Affairs
Adelle Coetzee
Moses Motlhageng - Chief Executive of Impala Rustenburg & CEO of Rustenburg Operations
Sifiso Sibiya - Group Executive of Refining & Marketing
Kirthanya Pillay - Group Executive of Corporate Development

Conference Call Participants

Christopher Nicholson - Morgan Stanley, Research Division
Gerhard Engelbrecht - Absa Bank Limited, Research Division
Arnold Van Graan - Nedbank Corporate and Investment Bank, Research Division
Nkateko Mathonsi - Investec Bank Limited (SA), Research Division

Presentation

Nicolaas Muller
CEO & Executive Director

Good morning to everyone. Welcome here to all those present, the investment community, our own Implats people and for everyone who's dialed in as well, welcome. Always an honor to represent a very talented Implats team. Extraordinary times that we are living in.

We had a presentation from one of the consulting firms the other day, and it was very clear that we are going through a shift in global order. It's a new era that is being introduced. We're seeing changes in international relationships, institutions, NATO, trade paths are changing, supply chains are changing. The move from globalization to multipolarity is accelerating. We just recently this weekend seen a new event unfold in the Middle East. And so all of this creates a number of consequences, one of which is uncertainty in future supply, particularly in natural resources and in our case, critical minerals and metals.

And critical can be defined in many ways. But one is, if it's used in critical industries like in Europe, the auto industry is a very important employer. It affects politics. And so without our metals, there is a risk for the industry. But

HomeIndustriesComputers/ElectronicsEarnings OutlookEarnings OutlookThe chip maker said it has visibility into more than $100 billion in AI chip revenue in 2027, and some analysts see even more upsidePublished: March 5, 2026 at 2:58 p.m. ET

Shares of Broadcom were climbing on Thursday, as investors looked to the company’s strong earnings report and upbeat outlook for its custom chip business to distract them from a broad selloff in the chip sector as well as in the overall stock market.

Broadcom AVGO CEO Hock Tan said during the post-earnings call with analysts late Wednesday there was a “line of sight” into more than $100 billion in revenue from its artificial-intelligence chips in 2027. The company’s custom AI chip ramps with its five major customers are “progressing very well,” Tan said. For the current quarter, Broadcom expects revenue to grow 140% over the previous year, to $10.7 billion.

Key Takeaways BDX secured FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system.The ready-to-use sterile solution helps remove debris and microorganisms during wound irrigation in surgery.The new 1000mL format expands BD's Surgiphor portfolio with both manual and powered irrigation options. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system. The product is the first antimicrobial irrigation solution available in a 1000mL format designed for powered lavage, providing a standardized and OR-ready option to support surgical safety and procedural performance. The Surgiphor 1000mL expands BD’s existing Surgiphor portfolio and enables clinicians to mechanically remove debris and microorganisms from wounds during powered irrigation procedures.

Per management, the FDA clearance further strengthens the company’s leadership in surgical irrigation technologies. The Surgiphor 1000mL antimicrobial irrigation system is designed to deliver consistent and safe irrigation performance, supporting surgical teams in improving procedural efficiency and patient care outcomes.

Likely Trend of BDX Stock Following the NewsShares of BDX have lost 1.6% since the announcement on Monday. Over the past six months, shares of the company declined 10.9% against the industry’s 23.3% growth and the S&P 500’s 6.4% rise.

In the long run, the FDA 510(k) clearance for BD’s Surgiphor 1000mL is expected to strengthen the company’s position in the wound irrigation systems market. By expanding the Surgiphor platform with a larger-volume powered irrigation option, the company can strengthen adoption across hospitals that rely on standardized, ready-to-use solutions to improve surgical outcomes and operational efficiency. The innovation also supports BDX’s broader strategy of expanding its surgery portfolio with integrated solutions that combine devices, consumables and clinical workflow support, which could help drive recurring product demand and strengthen hospital partnerships.

BDX currently has a market capitalization of $49.60 billion.

Image Source: Zacks Investment Research

More on the Surgiphor 1000mLThe Surgiphor 1000mL antimicrobial irrigation system is supplied as a ready-to-use sterile solution, eliminating the need for manual mixing by hospital staff. This design helps reduce preparation time in the operating room while supporting adherence to established safety standards for surgical wound irrigation. Building on the market adoption of the original Surgiphor antimicrobial irrigation system, the 1000mL configuration provides operating room teams with a higher-volume option designed to integrate with existing powered irrigation systems.

Engineered to work with widely used powered lavage devices, the system features a powered-device adapter along with a Y-connector that allows clinicians to switch between saline and Surgiphor solution during procedures. A twist cap is also included to support manual application when needed, providing additional flexibility for different clinical scenarios.

The design incorporates integrated venting to facilitate consistent and uninterrupted fluid flow, while the collapsible bottle structure helps ensure efficient evacuation and easier handling during use. The solution contains terminally sterile PVP-I (povidone-iodine) and forms part of BD’s broader surgical irrigation portfolio, offering terminally sterile PVP-I solutions in multiple volumes and delivery formats.

With the introduction of the 1000mL configuration, the Surgiphor antimicrobial irrigation system portfolio now includes both manual and powered irrigation options, allowing clinicians to choose formats that best align with procedural requirements and operating room workflows.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the wound irrigation systems market is valued at $356.16 million in 2026 and is expected to witness a CAGR of 4.7% through 2035.

Factors like the increasing chronic wound cases and the adoption of advanced, automated devices that improve infection control and healing efficacy are boosting the market’s growth.

Other NewsBD recently introduced the BD Vacutainer Urine Complete Cup Kit, a three-tube urine collection system aimed at expanding diagnostic testing from a single specimen. The launch highlights the company’s efforts to improve preanalytical workflows and laboratory efficiency. The kit is designed to preserve specimen integrity, reduce healthcare worker exposure and minimize repeat collections. Its unique third-tube configuration allows additional testing from one sample while eliminating manual transfers, thereby lowering contamination risks and improving operational safety in clinical environments.

In January, BD announced the commercial launch of BD Research Cloud 7.0, advancing its AI strategy in flow cytometry and life sciences research. The release features BD Horizon Panel Maker, an AI-driven tool that automates panel design — an essential step in immunology and oncology experiments to improve data quality and reliability. The cloud-based platform supports collaboration, workflow optimization and laboratory management.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #4 (Sell).

Some top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .

Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.

Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.

Want more housing market stories from Lance Lambert’s ResiClub in your inbox? Subscribe to the ResiClub newsletter.

After taking a big macro hit during the 2022 rate-shock, United Wholesale Mortgage’s (UWM) refinance volume has found its footing—and keeps climbing:

2020: $140B 2021: $139B 2022: $36B 2023: $14B (cycle low) 2024: $43B 2025: $70B That’s a +387% increase in UWM’s refi volume since its 2023 cycle low.

Even without a full refi boom, refinance volume is slowly coming back, with the average 30-year fixed mortgage rate as tracked by Freddie Mac down to 5.98% last week—or 1.81 bps below its cycle high of 7.79% in October 2023.

Many recent borrowers who took on higher mortgage rates (2023–2024 vintages) are jumping at the opportunity to refinance and secure some payment relief. At the same time, UWM’s purchase volume has remained relatively steady in the $90B–$96B range over the past few years.

The lack of a sharp decline in purchase volume following the rate-shock is impressive when you consider the macro picture: While U.S. existing home sales fell sharply in 2022, UWM’s purchase volume held steady as the wholesale channel gained share during the downturn. Many smaller lenders pulled back or exited, and brokers consolidated volume toward large, price-competitive players. UWM kept pushing forward. That purchase stability gives UWM a great base to operate from as refis improve.

While UWM’s refinance rebound is happening faster than most mortgage firms (and as a result, it’s taking refinance market share), refinance activity overall is slowly bouncing off the rate-shock lows.

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Horizon Technology Finance Corporation (NASDAQ: HRZN). The investigation focuses on Horizon Technology Finance executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Horizon Technology Finance securities?

If you purchased Horizon Technology Finance securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation

On March 3, 2026, Horizon Technology Finance Corporation announced its fourth quarter and full year 2025 financial results. The Company reported net investment income of $0.18 per share for the fourth quarter of 2025, down from $0.32 per share in the third quarter of 2025. 

Following these disclosures, Horizon Technology Finance common stock fell approximately 23% over the next trading day.

In light of these disclosures, Johnson Fistel is investigating whether Horizon Technology Finance complied with the federal securities laws. If you suffered losses from your investment in Horizon Technology Finance stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements

In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected] 

Key Takeaways Reblozyl tops $2.3B annualized sales, driving Bristol Myers growth amid declining legacy drug revenues.BMY reports data showing Reblozyl improved hemoglobin and reduced transfusion burden in alpha-thalassemia.Competition is rising as Keros tests elritercept in Phase III and Geron's Rytelo gains traction in MDS anemia. Bristol Myers (BMY - Free Report) is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line growth amid a significant decline in legacy drug sales.

Among these, Reblozyl, the thalassemia drug that BMY co-developed with Merck, continues to be a major growth driver, with annualized sales now exceeding $2.3 billion.

Reblozyl is indicated for the treatment of anemia in adult patients with transfusion-dependent and non-transfusion-dependent beta thalassemia who require regular red blood cell (RBC) transfusions. It is also approved for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts (RS) and require RBC transfusions, as well as for adult patients with very low- to intermediate-risk MDS who are ESA-naïve and may require regular RBC transfusions, regardless of RS status.

Sales in the United States are being driven by strong demand in first-line RS-positive and RS-negative myelodysplastic syndrome-associated anemia. International sales growth is being driven by strong launches in new markets.

BMY expects continued strong growth opportunities, particularly in the RS-negative MDS indication.

Last month, BMY reported positive top-line results from an ongoing ex-U.S. Phase 2 registrational study evaluating Reblozyl for anemia in adults with alpha-thalassemia.

Both non-transfusion-dependent and transfusion-dependent patient cohorts met their primary endpoints. Reblozyl significantly increased hemoglobin levels in non-transfusion-dependent patients and reduced red blood cell transfusion burden in transfusion-dependent patients. The study also met all key secondary endpoints, with safety results consistent with the drug’s established profile.

The data will be presented at an upcoming medical meeting and discussed with China’s drug regulator.

Approval in additional geographies should further boost sales.

Competition for BMY’s ReblozylKeros Therapeutics (KROS - Free Report) , a clinical-stage biopharmaceutical company, is evaluating elritercept, in partnership with Takeda, for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and patients with myelofibrosis.

A phase III study, RENEW, is evaluating elritercept for the treatment of anemia and thrombocytopenia in patients with very low-, low-, or intermediate-risk MDS.

In July 2025, KROS announced that the first patient had been dosed in the RENEW study. This triggered a $10 million milestone payment to Keros under its global licensing agreement with Takeda.

Reblozyl also competes with established ESAs like Procrit (epoetin alfa), though it works through different mechanisms.

Geron Corporation’s (GERN - Free Report) Rytelo (imetelstat) is also approved for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.

Geron is witnessing strong uptake of Rytelo since its approval in June 2024. The drug generated $183.6 million in 2025. Geron expects Rytelo sales in the range of $220 million to $240 million in 2026.

BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 20.6% in the past year compared with the industry’s growth of 4.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock currently trades at 10.05x forward earnings, higher than its mean of 8.46x but lower than the large-cap pharma industry’s 18.22x.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 EPS has moved north to $6.26 from $6.08 in the past 30 days, while that for 2027 has moved up to $6.07 from $5.88, 

Image Source: Zacks Investment Research